Straits Times Index
3,303.66 +12.96 (+0.39%) S&P 500
5,224.79 +2.11 (+0.04%) Dow
39,534.64 +21.80 (+0.06%) Nasdaq
16,387.71 +46.84 (+0.29%) Bitcoin USD
62,780.73 +1,625.97 (+2.66%) CMC Crypto 200
1,293.94 +33.73 (+2.68%)
Oncotelic Therapeutics, Inc. (OTLC)
| Previous close | 0.0382 |
| Open | 0.0360 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 0.0352 - 0.0390 |
| 52-week range | 0.0100 - 0.0500 |
| Volume | |
| Avg. volume | 62,849 |
| Market cap | 15.987M |
| Beta (5Y monthly) | 0.03 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0200 |
| Earnings date | 18 May 2024 - 22 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireONCOTELIC PRESENTING AT BIOPHARMA NEXUS CONFERENCE SAN DIEGO 2024
AGOURA HILLS, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its presentation at Biopharma Nexus Conference. Dr. Andy Hu, Nanomedicine Manager, will be presenting: Nanomedicines: Past, Present, Future. For additional information please go to: https://nexus-conference.com/ddnwest/. Dr. Hu is an experienced Biomaterial Scientist with expertise in nanomedicine, biologics, vaccines, cell, in vivo, gene therapy, drug development processes. He has gre
- GlobeNewswire
Oncotelic Therapeutics, Inc. to Sell Its Necroptosis Cancer Therapy Assets to Mosaic ImmunoEngineering, Inc.
AGOURA HILLS, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), announced today that it has entered into a binding term-sheet with Mosaic ImmunoEngineering, Inc. (OTCPK: CPMV) (“Mosaic”) under which Mosaic will acquire rights to Oncotelic’s clinical-stage necroptosis cancer therapies. Oncotelic’s necroptosis therapeutics work by disrupting tumor blood flow resulting in immunogenic tumor cell death through “death re
- GlobeNewswire
Linkage of Cancer and Lupus in Gliomas Patients
AGOURA HILLS, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today the peer reviewed publication of Transforming Growth Factor Beta 2 (TGFB2) mRNA Levels, in Conjunction with Interferon-Gamma Receptor Activation of Interferon Regulatory Factor 5 (IRF5) and Expression of CD276/B7-H3, Are Therapeutically Targetable Negative Prognostic Markers in Low-Grade Gliomas: Past, Present, and Future Strategies in the Treatment and Management of Gliomas. Dr. Vuo
